We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. Read more about our Privacy Policy.

I got it!

Event
26 Sep 2018
Biotechnology

SMi's 9th Annual Biosimilars and Biobetters

Forecasting the next wave of biosimilars to ensure optimal market commercialisation

The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. 

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.

After over a decade, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe.

We are now entering a very exciting time, for over the next few years several originator patents are expiring, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer, prescriber and patient to switch?

Join us to hear experiences of key opinion leaders and evaluate market access, opportunities and commercialisation strategies with industry-thought experts.

CHAIR FOR 2018:

  • Michel Mikhail, Global Expert in Biosimilars

FEATURED SPEAKERS:

  • Erin Federman, Head of Biologics, Europe, Mylan
  • Richard Trollope, Head of Biosimilars, Mundipharma International
  • Richard Peck, Vice President Regulatory Affairs, Lupin
  • Mourad Farouk Rezk, Senior Director, Global Head Medical Affairs Biosimilars, Biogen
  • Michael Muenzberg, Member, Comparative Outcomes Group and Former EU Medical Director, Biosimilars, Amgen
  • Daotian Fu, General Manager, Livzon Mabpharma
  • Rüdiger Jankowsky, Managing Director, Cinfa Biotech
  • Uwe Gudat, Head of Clinical Safety & Pharmacovigilance, Fresenius-Kabi
  • Ekkehard Brockstedt, Team Leader Outsourced Trials, Boehringer Ingelheim
  • Meenu Wadhwa, Section Leader, Cytokines and Growth

This event is CPD accredited.

#SMiBioSim

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS

Tuesday 25th September 2018, Copthorne Tara Hotel, Central London, UK

A: Global Development of Biosimilars: A Refresher
-

Workshop Leader: Michel Mikhail, Global Expert in Biosimilars

B: Value Based Agreements with Biosimilars: Architecture of Value Based Agreements
-

Workshop Leader: Omar Ali, Visiting Lecturer Value Based Pricing, University of Portsmouth & Former Adviser, NICE

WHO SHOULD ATTEND
Chief Executives, Vice Presidents, Executive Directors, Directors, Heads, Managers and Specialists
from the following, but not limited to, sectors should attend:

  • Biosimilars / Biologics
  • Biopharmaceuticals
  • Research and Development
  • Legal Affairs
  • Intellectual Property
  • Regulatory Compliance
  • Quality affairs and control
  • Pharmacovigilance, Drug Safety and Risk Management
  • Business Development
  • Commercialisation
  • Marketing and sales

EARLY BIRD-RATES

  • BOOK BY 31ST MAY AND SAVE £300
  • BOOK BY 29TH JUNE AND SAVE £200

When

26 Sep 2018 @ 08:30 am

27 Sep 2018 @ 04:30 pm

Duration: 1 days, 8 hours


Where

Copthorne Tara Hotel, Central London, UK

1 Scarsdale Place

Kensington

United Kingdom


Language

English en


Organised by

SMi Group Ltd.

Other Events in Science

Similar Webinars in Science

EU NTC ten year anniversary event

Webinar, 30 May 2024

Recent Publications in Science

PASSENGER: a solution for futureproof permanent magnets made in Europe

Fact-sheet, Apr 2024, ESF - PASSENGER project